Dibrospidium chloride

Dibrospidium chloride
INN: Dibrospidium chloride
Clinical data
Other names	Spirobromin, spirobromine
ATC code	L01 ;
Identifiers
	IUPAC name 3,12-Bis(3-bromopropanoyl)-3,6,9,12-tetraazadispiro[5.2.5~9~.2~6~]hexadecane-6,9-diium dichloride;
CAS Number	86641-76-1;
PubChem CID	72114;
ChemSpider	65092;
UNII	GRX5L9Y3Z3;
ChEMBL	ChEMBL2106677;
CompTox Dashboard (EPA)	DTXSID101006989 ;
Chemical and physical data
Formula	C18-H32-Br2-N4-O2.2Cl
Molar mass	567.191
3D model (JSmol)	Interactive image;
	SMILES [Cl-].[Cl-].BrCCC(=O)N1CC[N+]2(CC1)CC[N+]3(CCN(CC3)C(=O)CCBr)CC2;
	InChI InChI=InChI=1S/C18H32Br2N4O2.2ClH/c19-3-1-17(25)21-5-9-23(10-6-21)13-15-24(16-14-23)11-7-22(8-12-24)18(26)2-4-20;;/h1-16H2;2*1H/q+2;;/p-2; Key:CURYRIVJTBNEGU-UHFFFAOYSA-L;

Dibrospidium chloride, also known as spirobromin, is a drug being investigated to treat bone cancer. It has potential anti-inflammatory and anti-neoplastic properties. It is an alkylating antineoplastic agent.^[1]^[2]

Dibrospidium chloride and related compounds were developed in Russia in the 1980s.^[3]^[4] It is currently used in Russia as a cytostatic antitumor chemotherapeutic drug.^[5]

References

^ Chambers M. "CAS - 86641-76-1 - CURYRIVJTBNEGU-UHFFFAOYSA-L - Dibrospidium chloride [INN]". ChemIDplus. U.S. National Library of Medicine. Retrieved 25 May 2022.
^ "Dibrospidium Chloride". PubChem. U.S. National Library of Medicine. Retrieved 25 May 2022.
^ Safonova TS, Chernov VA, Minakova SM, Dorokhova MI, Levkovskaya LG, Traven' NI, et al. (1983). "New antitumor agent — Spirobromin". Pharmaceutical Chemistry Journal. 17 (5): 375–377. doi:10.1007/BF00765650. S2CID 43730360.
^ Safonova TS, Minakova SM, Chernov VA, Andreyanova TA, Deev VV (1984). "Dependence of the antitumor activity of spirobromin analogs on their structure". Pharmaceutical Chemistry Journal. 18 (12): 803–806. doi:10.1007/BF00768330. S2CID 9795933.
^ Egorova A, Bogner E, Novoselova E, Zorn KM, Ekins S, Makarov V (February 2021). "Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)". European Journal of Medicinal Chemistry. 211: 113014. doi:10.1016/j.ejmech.2020.113014. PMC 7658596. PMID 33218683. S2CID 226300593.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Chambers M. "CAS - 86641-76-1 - CURYRIVJTBNEGU-UHFFFAOYSA-L - Dibrospidium chloride [INN]". ChemIDplus. U.S. National Library of Medicine. Retrieved 25 May 2022.

[2] "Dibrospidium Chloride". PubChem. U.S. National Library of Medicine. Retrieved 25 May 2022.

[3] Safonova TS, Chernov VA, Minakova SM, Dorokhova MI, Levkovskaya LG, Traven' NI, et al. (1983). "New antitumor agent — Spirobromin". Pharmaceutical Chemistry Journal. 17 (5): 375–377. doi:10.1007/BF00765650. S2CID 43730360.

[4] Safonova TS, Minakova SM, Chernov VA, Andreyanova TA, Deev VV (1984). "Dependence of the antitumor activity of spirobromin analogs on their structure". Pharmaceutical Chemistry Journal. 18 (12): 803–806. doi:10.1007/BF00768330. S2CID 9795933.

[5] Egorova A, Bogner E, Novoselova E, Zorn KM, Ekins S, Makarov V (February 2021). "Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)". European Journal of Medicinal Chemistry. 211: 113014. doi:10.1016/j.ejmech.2020.113014. PMC 7658596. PMID 33218683. S2CID 226300593.

[1]

[2]

[3]

[4]

[5]